PRECLINICAL STUDY

An Elastic, Biodegradable Cardiac Patch Induces Contractile Smooth Muscle and Improves Cardiac Remodeling and Function in Subacute Myocardial Infarction

Kazuro L. Fujimoto, MD,*† Kimimasa Tobita, MD,†‡§ W. David Merryman, PhID,§ Jianjun Guan, PhID,*† Nobuo Momoi, MD, PhID,‡ Donna B. Stolz, PhID,§ Michael S. Sacks, PhID,†§ Bradley B. Keller, MD,†‡|| William R. Wagner, PhID*†§

Pittsburgh, Pennsylvania

Objectives  Our objective in this study was to apply an elastic, biodegradable polyester urethane urea (PEUU) cardiac patch onto subacute infarcts and to examine the resulting cardiac ventricular remodeling and performance.

Background  Myocardial infarction induces loss of contractile mass and scar formation resulting in adverse left ventricular (LV) remodeling and subsequent severe dysfunction.

Methods  Lewis rats underwent proximal left coronary ligation. Two weeks after coronary ligation, a 6-mm diameter micro-porous PEUU patch was implanted directly on the infarcted LV wall surface (PEUU patch group, n = 14). Sham surgery was performed as an infarction control (n = 12). The LV contractile function, regional myocardial wall compliance, and tissue histology were assessed 8 weeks after patch implantation.

Results  The end-diastolic LV cavity area (EDA) did not change, and the fractional area change (FAC) increased in the PEUU patch group (p < 0.05 vs. week 0), while EDA increased and FAC decreased in the infarction control group (p < 0.05). The PEUU patch was largely resorbed 8 weeks after implantation and the LV wall was thicker than infarction control (p < 0.05 vs. control group). Abundant smooth muscle bundles with mature contractile phenotype were found in the infarcted myocardium of the PEUU group. The myocardial compliance of the PEUU group was distributed between normal myocardium and infarction control (p < 0.001).

Conclusions  Implantation of a novel biodegradable PEUU patch onto a subacute myocardial infarction promoted contractile phenotype smooth muscle tissue formation and improved cardiac remodeling and contractile function at the chronic stage. Our findings suggest a new therapeutic option against post-infarct cardiac failure. (J Am Coll Cardiol 2007;49:2292–300) © 2007 by the American College of Cardiology Foundation

Postinfarct left ventricular (LV) remodeling is a well-described compensatory mechanism of congestive heart failure (CHF), characterized by progressive ventricular chamber dilatation, wall thinning, and sphericity that allows the failing ventricle to maintain cardiac output by increasing stroke volume. This compensatory mechanism in the long-term causes maladaptive changes in myocardial structural and function (1,2). Among clinical indicators, LV dilation and increased LV sphericity are sensitive predictors of poor long-term outcome and mortality (3). Therapeutic strategies to antagonize LV remodeling, such as angiotensin-converting enzyme inhibitors and/or beta-blockers, have proven beneficial in treating CHF (4). Despite the value of such medical approaches, progression from myocardial infarction to CHF remains a tremendous burden in terms of morbidity and mortality as well as financial cost.

Surgical approaches have been proposed that are based on the concept of reducing the LV cavity volume to restore wall tension toward normal levels, thus interrupting the remodeling process and improving hemodynamic status. Both the endoventricular circular patch plasty technique (the Dor procedure) (5,6) and partial left ventriculectomy (the Batista procedure) (7) have been clinically implemented. However, these therapies are restricted to patients with severe dilation and dysfunction many years after an infarction. Another surgical approach that has been investigated is epicardial restraint therapy, where a wrap is applied over the cardiac surface from the apex upward. The Acorn Cardiac Support Device (Acorn Cardiovascular, St. Paul, Minnesota), which

From the *Department of Surgery, †McGowan Institute for Regenerative Medicine, ‡Department of Pediatrics, Children’s Hospital of Pittsburgh, §Department of Bioengineering, and the ||Department of Cell Biology and Physiology, University of Pittsburgh, Pittsburgh, Pennsylvania. This work was supported by the National Heart, Lung, and Blood Institute, grant HL069368.

Manuscript received October 23, 2006; revised manuscript received January 31, 2007, accepted February 18, 2007.
is comprised of a polyester mesh (8), and the Paracor device
(Paracor Medical, Inc., Sunnyvale, California), which util-
izes a nitinol mesh (9), employ this strategy. These ap-
proaches both utilize nonbiodegradable materials and result
in a permanent foreign body encapsulating the epicardium.
More recently, several groups have pursued tissue engineer-
ing approaches for ventricular wall reconstruction surgery
(10–12), in contrast to the wide variety of cellular injection
approaches currently under investigation (13). The feasibil-
ity of translating these latter approaches to the clinic remains
challenging with concerns about cell sourcing and character-
ization, and the practicalities of in vitro patch development
being of concern.

Given these observations, we hypothesized that an attrac-
tive approach to the management of LV dilation would be
to apply an elastic patch to the infarcted ventricle where the
patch was not a wrap, but might be sized to the infarct, and
where the patch was both highly elastic and biodegradable
so that the material would erode over several weeks. By
avoiding cellular components, the approach might be more
readily translatable to clinical investigations. Toward this
end, we have designed and developed a porous, elastic
scaffold from a biodegradable elastomer that can be pro-
cessed into a variety of formats compatible with cardiovas-
cular placement (14,15). Our objective in this study was to
apply this scaffold as a cardiac patch onto subacute infarcts
that had developed over a 2-week period after coronary
ligation in the rat model and to examine the resulting
cardiac performance and ventricular remodeling. Our hy-
pothesis was that placement of this patch would alter the
progression of remodeling, which leads to ventricular wall
thinning and fibrosis, and would preserve contractile
function.

Methods

Experimental animals. Adult female Lewis rats (Harlan
Sprague Dawley, Indianapolis, Indiana) weighing 200 g to
250 g were used. The protocol followed National Institutes
of Health guidelines for animal care and was approved by
the University of Pittsburgh’s Institutional Animal Care and
Use Committee and Children’s Hospital of Pittsburgh
Animal Research Care Committee.

Elastomeric biodegradable microporous polyester ure-
thane urea (PEUU) patch. The circular PEEU patch was
made of a polyester urethane urea that was synthesized in
the investigators’ laboratory as previously described (14),
and processed using thermally induced phase separation
techniques (15) into a patch with interconnected micropores
(Fig. 1A). The patch possessed 91% porosity and a 91-μm
average pore size. Mechanically, the patch was elastic with
a tensile strength of 0.78 MPa and elongation at rupture of
157%. The material was sized to circular patches 6 mm in
diameter × 300 μm thick (Fig. 1B). The patches were
immersed in 100% ethanol for 30 min, followed by immer-
sion in phosphate-buffered saline and exposure to the ultraviolet
light source for 1 h before implantation.

Proximal left coronary artery ligation. Animal anesthesia was
induced by 3.0% isoflurane inhalation followed by intubation and
connection to a rodent volume-controlled mechanical ventilator.
The heart was exposed through a left thoracotomy, monitoring elec-
trocardiogram, and tail cuff blood pressure. The proximal left anterior
descending coronary artery was ligated with 7-0 polypropylene. Myo-
cardial ischemia was confirmed by regional cyanosis and ST-segment
elevation. The incision was closed in layers with 4-0 silk continuous
sutures.

PEEU patch implantation. Two weeks after coronary artery liga-
tion, animals were anesthetized and examined echocardio-
graphically for infarct size as estimated by the percentage of
scar area (akineti c or dyskinetic regions) to LV free wall area
(11). A total of 26 rats with infarcts greater than 25% of the
LV free wall were divided into 2 groups: PEEU patch repair
(patch group; n = 14) and sham repair (infarction control
group; n = 12). Through a left thoracotomy, the infarcted
anterior wall was exposed. Before affixing the patch, the
surface of the infarcted area (less than 0.1 mm thickness),
including the remnant epicardium and some of the inte-
grated fibrous tissue, was scraped and removed at the patch
implant site. Using 7-0 polypropylene with over-and-over
peripheral sutures, the anterior infarcted myocardium was
covered with a PEEU patch. For the infarction control
group, a thoracotomy was performed 2 weeks after coronary
ligation, but no scraping or patch placement was performed.
Six age-matched rats without coronary ligation or surgical
intervention served as a control group.

Histology. Eight weeks after patch implantation (10 weeks
after myocardial infarction), rats in both surgical groups
were anesthetized, and the heart was exposed and arrested
by apical injection of 2 ml of a hypothermic arresting
solution (68 mmol/l NaCl, 60 mmol/l KCl, 36 mmol/l
NaHCO3, 2.0 mmol/l MgCl2, 1.4 mmol/l Na2SO4, 11
mmol/l dextrose, 30 mmol/l butanedione mono-oxime,
10,000 U/l of heparin). The embedded frozen LV tissues
were serially sectioned at 8 μm in the LV transverse
direction. Hematoxylin and eosin staining and immunohis-
stochemical staining were performed as previously described
(16) with antibodies against alpha-smooth muscle actin
(SMA) (Sigma, St. Louis, Missouri), CD 31 (Serotec,
Raleigh, North Carolina), caldesmon (Abcam, Cambridge,
Massachusetts), calponin (Abcam), smooth muscle myosin heavy chain 2 (SMMHC-2, Abcam), SM-22α (Abcam), basic fibroblast growth factor (bFGF, Serotec), or vascular endothelial growth factor (VEGF, Santa Cruz Biotechnology, Santa Cruz, California). Nuclei were stained with 4',6-Diamidino-2-phenylindole (DAPI, Sigma). To observe the pattern of -SMA–positive staining across the infarcted wall, 5 to 7 fields at 100× were digitally photographed for each heart and composite images assembled (NIH image and Adobe Photoshop, San Jose, California) (n = 5 rats/group).

LV wall thickness and capillary density. For each LV sample, 5 different microscopic fields at 100× for the wall thickness measurement and 10 different fields at 200× for capillary density were photographed for each rat. The wall thickness of the infarcted anterior wall (patch implanted region) was analyzed using NIH Image software for patch and infarction control groups (n = 5 rats/group). Capillaries were recognized as tubular structures positively stained for CD31 as previously described (16).

Transmission electron microscopy. Two hearts from each group were processed and imaged with transmission electron microscopy as previously described (17). Thin sections (80 nm) were examined with JEOL 1210 TEM system (JEOL USA, Peabody, Massachusetts). Digital images were obtained using a side-mount AMT 2k digital camera (Advanced Microscopy Technologies, Danvers, Massachusetts).

Echocardiography. Echocardiography was performed at the time of patch implantation (0 weeks, 2 weeks postinfarction), 4 and 8 weeks after patch implantation. The same time points were measured for all groups. Rats were anesthetized with isoflurane inhalation. Standard transthoracic echocardiography was performed using the Acuson Sequoia C256 system with 13-MHz linear ultrasonic transducer (15L8; Acuson Corporation, Mountain View, California) in a phased-array format. B-mode measurements on the LV short-axis view (papillary muscle level) were performed (16). The end-diastolic (EDA) and end-systolic (ESA) LV internal cavity areas were measured by tracing the endocardial
the cardiac tissue and restored the LV wall thickness in the infarction region relative to hearts from the infarction control group.

**Histology.** In examining histological sections stained with hematoxylin and eosin, it was seen that the majority of the PEUU patch was absorbed and the remnant area of the patch appeared to be infiltrated with macrophages and fibroblasts. The ventricular walls to which PEUU patches were applied were thicker and contained more dense and muscle-like bundles than the infarction control (Figs. 2A and 2B). The muscle-like bundles were found under the patch regions stained positively for α-SMA (Figs. 2C to 2F). Reviewing α-SMA expression across the infarct region from 5 random samples in each experimental group demonstrated that in the infarction control group, α-SMA was sporadically expressed and primarily associated with vascular structures in all samples. In contrast, for the PEUU patch group, there were 2 patterns of α-SMA staining: a uniform distribution of α-SMA–positive tissue beneath the whole patch area, or clustered regions of α-SMA–positive tissue. Further immunohistochemical staining demonstrated that caldesmon, calponin, SM 22α, and SMMHC-2 (Fig. 3A), proteins that are associated with contractile function, co-localized with α-SMA–positive cells. Electron micrographs of the muscle-like bundles demonstrated that the aligned cells were rich in myofibrils and clustered mitochondria typical of smooth muscle cell ultrastructure. Numerous caveolae along the membrane and dense bodies within the cytoplasm were observed, strongly suggesting a smooth muscle phenotype (Figs. 3B to 3D).

**Wall thickness and capillary density.** From histological section analysis, the LV myocardial wall for the PEUU implantation group was found to be thicker than that in the infarction control group (985 ± 90 μm vs. 480 ± 62 μm, p < 0.01). The capillary density of the PEUU patch group was significantly increased compared with that in the infarction control group (275 ± 56/mm² vs. 102 ± 17/mm², p < 0.05).

**Growth factor expression.** Basic fibroblast growth factor and VEGF immunohistochemical staining (Figs. 4A to 4D) demonstrated expression of both growth factors around the PEUU patch regions stained positively for α-SMA (Figs. 4C to 4D). Reviewing α-SMA expression across the infarct region from 5 random samples in each experimental group demonstrated that in the infarction control group, α-SMA was sporadically expressed and primarily associated with vascular structures in all samples. In contrast, for the PEUU patch group, there were 2 patterns of α-SMA staining: a uniform distribution of α-SMA–positive tissue beneath the whole patch area, or clustered regions of α-SMA–positive tissue. Further immunohistochemical staining demonstrated that caldesmon, calponin, SM 22α, and SMMHC-2 (Fig. 3A), proteins that are associated with contractile function, co-localized with α-SMA–positive cells. Electron micrographs of the muscle-like bundles demonstrated that the aligned cells were rich in myofibrils and clustered mitochondria typical of smooth muscle cell ultrastructure. Numerous caveolae along the membrane and dense bodies within the cytoplasm were observed, strongly suggesting a smooth muscle phenotype (Figs. 3B to 3D).

**Statistics.** All data are expressed as mean ± standard deviation. Analyses utilized SPSS software (SPSS Inc., Chicago, Illinois). The wall thickness in each group was compared by Student t test. Echocardiography data and P-E analyses were compared by 2-way repeated analysis of variance with Tukey’s test. Statistical significance was defined at a value of p < 0.05.

**Results**

**External morphology.** There were no early or late postoperative deaths in either surgical group. After an 8-week implantation period, the PEUU patch material was found to have formed no strong adhesions with the chest wall, and its surface was covered with connective tissue (Figs. 1C and 1F). In examining the heart in transverse cross section, it was consistently found that the patch was well merged with
larger than that of the patch group. The %FAC was increased in the patch group at 8 weeks relative to the time of patch implantation, while for the infarction control group the %FAC had significantly decreased by 8 weeks. The regional %FAC in the PEUU patch group at 8 weeks was significantly larger than that in the infarction control group (27 ± 9.0% vs. 15 ± 10%), which was similar to the global %FAC. It was noted that negative values of %FAC (dyskinetic) were obtained for 2 samples of the infarction control group, an effect not observed in the PEUU patch group.

**Regional LV myocardial compliance.** Both circumferential and longitudinal LV myocardial P-E curves (Fig. 6) revealed that at 8 weeks the LV wall had stiffened in the infarction control group (27 ± 9.0% vs. 15 ± 10%), which was similar to the global %FAC. It was noted that negative values of %FAC (dyskinetic) were obtained for 2 samples of the infarction control group, an effect not observed in the PEUU patch group.

**Discussion**

Our results demonstrated that implantation of an elastic, biodegradable PEUU patch onto the ventricular region of a subacute myocardial infarct in the rat model preserved LV geometry and improved contractile function relative to that in nontreated animals. This effect occurred even though the patch was placed 2 weeks after the time of LV infarction. During this clinically relevant lag period preceding intervention, the infarcted wall would be expected to have progressed through the necrotic phase and into the fibrotic phase (2). A particularly encouraging finding was the effect that patch placement had on tissue remodeling at the structural level with the development of smooth muscle bundles in the tissue below the patch and the alteration in myocardial wall thickness and compliance.

The PEUU material was chosen for its elastic mechanical properties, processability, expected biocompatibility, and biodegradability (14,15). It was shown that after 8 weeks of implantation, most of the material had degraded in vivo. By utilizing an elastic, degradable patch material, it was postulated that temporary alteration of the mechanical environment would provide benefit, and that by degrading, the PEUU material would avoid potential complications associated with a nondegradable material such as providing a chronic nidus for infection and calcification. Also, our experience with the regional application was a 0% mortality rate with minimal adhesion formation evident at the time of explant as well as no evidence of infection. Should this approach be scalable to humans, one would expect that the procedure could be performed in a low-risk manner and the mechanical properties of the PEUU material also were amenable to rolling, folding, or other compression techniques that might allow the patch to be placed minimally invasively.

Several possible mechanisms might explain the functional benefits associated with the patch. First, mechanical reinforcement provided by the PEUU material would acutely act to prevent further LV dilatation, which subsequently increases LV wall tension (6).
thickness, even after the patch had degraded, might reduce LV wall stress versus untreated infarct control. Finally, the regional myocardial compliance of patched myocardium approached that of normal myocardium and was significantly higher than infarction control, which stiffened. This near normal physiologic compliance might act to prevent further LV dilation and improve cardiac function. Our findings would appear to contradict the work of Pfeffer et al. (21) where it was reported that LV chamber compliance increases (by pressure-volume relations) after infarction. However, Omens et al. (22) demonstrated that the regional LV strain P-E response after infarction may not be well predicted by the overall LV chamber pressure-volume response. With respect to the abundant contractile smooth muscle cell bundles found in the LV walls of patched animals, there is no evidence that they contributed to LV function, and further studies would be necessary to examine this potential effect.

In considering the role of the inflammatory response associated with PEUU biodegradation, this phenomenon might act to enhance and extend the presence of granulation tissue in the infarct area, analogous to the effect pursued by Hayakawa et al. (23). The PEUU will degrade by hydrolysis and, when small enough particles are generated, be phagocytosed by macrophages at the implant site. We found pronounced expression of bFGF and VEGF around the vessels and smooth muscle bundles in the PEUU patch group with significantly increased capillary density relative to infarction control. These locally released angiogenic factors, potentially released by local macrophages, might positively influence tissue remodeling. In addition to material phagocytosis, the scraping procedure employed before patch placement might augment this local inflammatory response acutely. Further studies to define specific growth factor and cytokine release patterns would be warranted.

Several limitations of the current report should be mentioned. First, the beneficial effects in terms of cardiac function and LV remodeling were only observed in the 8-week period...
after patch implantation. Although the PEUU patch has substantially degraded in this period, the sustainability of the architectural and functional changes remains to be examined for longer periods of time. There might theoretically be some optimal time point when the patch would have provided its beneficial effect and degradation would be desired. To investigate this effect, the time course of patch degradation could be altered by manipulating the polymer chemistry while maintaining comparable mechanical properties (24). A second limitation of this report was employment of the rat model. Further exploration in a large animal model is needed where changes in the patched LV area and the volume of impacted LV wall more closely approximate the clinical setting. Finally, the origin of the smooth muscle cell bundles that appear in the patched LV wall has not been defined. Histological sections did not suggest an obvious migration of this tissue from the healthy periphery of the infarct. One hypothesis is that this tissue is derived from

Figure 4  
**bFGF and VEGF Immunohistochemical Staining**

Immunohistochemical staining for basic fibroblast growth factor (bFGF) (A and B) and vascular endothelial growth factor (VEGF) (C and D) in the polyester urethane urea patch (A and C) and infarction control (B and D) groups. The **left image of each set** shows growth factor and nuclear staining, and the **right image** merges in alpha-smooth muscle actin (α-SMA) staining. Growth factor staining is red, α-SMA staining is green, and nuclear staining is blue. Scale bars are 100 μm.

Figure 5  
**Echocardiographic Assessment**

Echocardiographic assessment of the polyester urethane urea patch, infarction control, and normal control groups during the study period. End-diastolic area is shown in (A), and % fractional area change in (B). End-diastolic area and % fractional area change in the normal control group were significantly different than those in the patch and infarction control groups (p < 0.05) at each time point and did not significantly vary during follow-up. *p < 0.05 between groups; †p < 0.05 versus just before implantation (pre) within group. 4w = 4 weeks after implantation; 8w = 8 weeks after implantation.
circulating cells rather than myocardial tissue. Employment of a marrow ablation model where a chimera with fluorescently labeled reconstituted marrow is obtained would permit investigation of this theory (25).

Conclusions

This report demonstrates that regional application of a biodegradable and elastic polyurethane cardiac patch prevented ventricular dilation and improved contractile function in a subacute rat infarction model. This approach might provide an attractive alternative to cellular cardiomyoplasty or larger ventricular restraint devices for cardiac repair.

Acknowledgments

The authors thank Jennifer Debarr, Katie Clark, Ana Lopez, Mara Sullivan, and Kenichi Tamama for their help with the tissue histological assessment, and Paul Bieniek for writing software code for biomechanical compliance measurements.

Reprint requests and correspondence: Dr. William R. Wagner, McGowan Institute for Regenerative Medicine, University of Pittsburgh, 100 Technology Drive, Pittsburgh, Pennsylvania 15219. E-mail: wagnerwr@upmc.edu.

REFERENCES